FDA Panel Mulls Safety Of Luitpold’s Intravenous Iron
This article was originally published in The Pink Sheet Daily
Executive Summary
“Mortality disadvantage” compared with oral?
You may also be interested in...
FDA Panel Votes Against First-line Use For Luitpold’s Iron Deficiency Drug Injectafer
Concerned about off-label use of the drug in patients with critical kidney disease, advisory committee suggests that if approved, Injectafer label should include “very descriptive prescribing” instructions.
FDA Panel Votes Against First-line Use For Luitpold’s Iron Deficiency Drug Injectafer
Concerned about off-label use of the drug in patients with critical kidney disease, advisory committee suggests that if approved, Injectafer label should include “very descriptive prescribing” instructions.
AMAG Seeks Dialysis And Pre-Dialysis CKD Indication For Ferumoxytol
A potential competitor, Luitpold’s Injectafer, is scheduled to go before an FDA advisory committee Feb. 1.